User Tools

Site Tools


documentation:oncology:meeting_notes_2019_jun-25

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
documentation:oncology:meeting_notes_2019_jun-25 [2019/06/27 14:09]
mgurley
documentation:oncology:meeting_notes_2019_jun-25 [2019/06/27 14:10] (current)
mgurley
Line 11: Line 11:
     * The group was asked for volunteers to write SQL to derive Hemonc.org oncology drug regimens from low-level DRUG_EXPOSURE and EPISODE oncology diagnosis entries. ​ Michael Gurley pointed to the following paper as a starting point: https://​ascopubs.org/​doi/​pdf/​10.1200/​CCI.17.00002     * The group was asked for volunteers to write SQL to derive Hemonc.org oncology drug regimens from low-level DRUG_EXPOSURE and EPISODE oncology diagnosis entries. ​ Michael Gurley pointed to the following paper as a starting point: https://​ascopubs.org/​doi/​pdf/​10.1200/​CCI.17.00002
     * Dmytry Dymshyts expressed doubt about the possibility of derivation of oncology drug regimens from discrete DRUG_EXPOSURE data and EPISODE oncology diagnosis entries.     * Dmytry Dymshyts expressed doubt about the possibility of derivation of oncology drug regimens from discrete DRUG_EXPOSURE data and EPISODE oncology diagnosis entries.
-    * The group agreed that validation of derivation will need to be compered ​to gold standard manually chart abstracted oncology drug regimens. ​ Possibly from clinical trials or registry patients.+    * The group agreed that validation of derivation will need to be compared ​to gold standard manually chart abstracted oncology drug regimens. ​ Possibly from clinical trials or registry patients.
     * Michael Gurley pointed out that some institutions'​ source systems will have pre-derived oncology drug regimens within their oncology drug regimen order template systems. ​ These folks are the "lucky ones".     * Michael Gurley pointed out that some institutions'​ source systems will have pre-derived oncology drug regimens within their oncology drug regimen order template systems. ​ These folks are the "lucky ones".
     * Michael Gurley mentioned that Jeremy Warner (one of the principal architects of Hemonc.org) ​ thinks that the use of NLP against oncologist progress notes will be necessary to derive oncology drug regimens.     * Michael Gurley mentioned that Jeremy Warner (one of the principal architects of Hemonc.org) ​ thinks that the use of NLP against oncologist progress notes will be necessary to derive oncology drug regimens.
documentation/oncology/meeting_notes_2019_jun-25.txt ยท Last modified: 2019/06/27 14:10 by mgurley